Herbal composition for treating metastatic breast cancer

Abstract

The invention provides a composition comprising a mixture of extracts obtained from Atractylodes macrocephala, Astragalus membranaceus, Taraxacum mongolicum, Poria cocos, Ligusticum chuanxiong, Ligustrum lucidum, Codonopsis pilosula, Glycyrrhiza uralensis, Hedyotis diffusa, Pseudostellaria heterophylla, and Viola philippica. The present invention further provides a method for treating metastatic breast cancer in a subject in need thereof, comprising: administering to said subject an pharmaceutically effective amount of the composition.

Claims

1. A method for treating metastatic breast cancer in a subject in need thereof, comprising: administering to said subject an pharmaceutically effective amount of a composition in the form of an aqueous composition comprising a mixture of extracts obtained from Atractylodes macrocephala, Astragalus membranaceus, Taraxacum mongolicum, Poria cocos, Ligusticum chuanxiong, Ligustrum lucidum, Codonopsis pilosula, Glycyrrhiza uralensis, Hedyotis diffusa, Pseudostellaria heterophylla, and Viola philippica.

2. The method of claim 1, wherein the extracts are organic solvent extracts.

3. The method of claim 2, wherein the organic solvent is selected from the group consisting of methanol, ethanol, acetic acid, ketone, hexane, propanol, isopropanol and chloroform.

4. The method of claim 1, wherein the extracts are obtained from the whole plants.

5. The method of claim 1, which has a concentration of ingredients as follows: 250 mg/mL of Atractylodes macrocephala, 330 mg/mL of Astragalus membranaceus, 500 mg/mL of Taraxacum mongolicum, 330 mg/mL of Poria cocos, 250 mg/mL of Ligusticum chuanxiong, 250 mg/mL of Ligustrum lucidum, 250 mg/mL of Codonopsis pilosula, 160 mg/mL of Glycyrrhiza uralensis, 330 mg/mL of Hedyotis diffusa, 250 mg/mL of Pseudostellaria heterophylla, and 160 mg/mL of Viola philippica.

6. The method of claim 1, wherein the metastatic breast cancer is refractory metastatic breast cancer.

7. The method of claim 1, wherein the composition improves global health status/quality of life (GHS/QOL) scale of the subject.

8. The method of claim 1, wherein the composition increases the level of CD3, CD4/CD8, CD19, and CD16+56 positive cells in the subject.

9. The method of claim 1, wherein the composition increases the physical, role, emotional, and cognitive functioning.

10. The method of claim 1, wherein the composition decreases fatigue and systemic therapy side effects.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 shows a flow diagram of the randomized, double-blind, placebo-controlled, parallel-group phase IIa clinical trial comparing Tien Hsien Liquid Practical (THL-P) to placebo for safety and efficacy. A total of 63 patients entered our trial between June 2009 and June 2011. Nineteen patients were excluded due to lack of confidence in the treatment (n=10), hospital transfer (n=2), and treatment refusal (n=7). Forty-four patients were randomly assigned in a 2:1 ratio to either the THL-P group (n=30) or the placebo group (n=14). Thirteen patients in the THL-P group, and none in the placebo group had completed the study.

(2) FIG. 2 shows the Primary endpoint of the intent-to-treat population. A) The standardized score of the global health/quality of life (GHS/QOL) scale of the European Organization for Research and Treatment of Cancer Quality of Life QuestionnaireCore 30 (EORTO-QLQ-C30). Values represent medians (interquartile ranges). P<0.05 vs. baseline (Wilcoxon signed ranks test). B) Changes in the standardized score of the GHS/QOL scale of the EORTO-QLQ-C30 in the intent-to-treat population. Treatment of Cancer Quality of Life QuestionnaireCore 30 (EORTO-QLQ-C30). Values represent medians (interquartile ranges). *P<0.05 vs. placebo (Mann-Whitney U test).

DETAILED DESCRIPTION OF THE INVENTION

(3) The present invention provides a composition comprising a mixture of extracts obtained from Atractylodes macrocephala, Astragalus membranaceus, Taraxacum mongolicum, Poria cocos, Ligusticum chuanxiong, Ligustrum lucidum, Codonopsis pilosula, Glycyrrhiza uralensis, Hedyotis diffusa, Pseudostellaria heterophylla, and Viola philippica.

(4) In one embodiment, the extracts are organic solvent extracts. Preferably, the organic solvent is selected from the group consisting of methanol, ethanol, acetic acid, ketone, hexane, propanol, isopropanol and chloroform.

(5) In another embodiment, the extracts are obtained from the whole plants.

(6) The composition of the present invention has a concentration of ingredients as follows: 250 mg/mL of Atractylodes macrocephala, 330 mg/mL of Astragalus membranaceus, 500 mg/mL of Taraxacum mongolicum, 330 mg/mL of Poria cocos, 250 mg/mL of Ligusticum chuanxiong, 250 mg/mL of Ligustrum lucidum, 250 mg/mL of Codonopsis pilosula, 160 mg/mL of Glycyrrhiza uralensis, 330 mg/mL of Hedyotis diffusa, 250 mg/mL of Pseudostellaria heterophylla, and 160 mg/mL of Viola philippica.

(7) The present invention further provides a method for treating metastatic breast cancer in a subject in need thereof, comprising: administering to said subject an pharmaceutically effective amount of a composition comprising a mixture of extracts obtained from Atractylodes macrocephala, Astragalus membranaceus, Taraxacum mongolicum, Poria cocos, Ligusticum chuanxiong, Ligustrum lucidum, Codonopsis pilosula, Glycyrrhiza uralensis, Hedyotis diffusa, Pseudostellaria heterophylla, and Nola philippica.

(8) In one embodiment, the extracts are organic solvent extracts. Preferably, the organic solvent is selected from the group consisting of methanol, ethanol, acetic acid, ketone, hexane, propanol, isopropanol and chloroform.

(9) In another embodiment, the extracts are obtained from the whole plants.

(10) The composition of the present invention has a concentration of ingredients as follows: 250 mg/mL of Atractylodes macrocephala, 330 mg/mL of Astragalus membranaceus, 500 mg/mL of Taraxacum mongolicum, 330 mg/mL of Poria cocos, 250 mg/mL of Ligusticum chuanxiong, 250 mg/mL of Ligustrum lucidum, 250 mg/mL of Codonopsis pilosula, 160 mg/mL of Glycyrrhiza uralensis, 330 mg/mL of Hedyotis diffusa, 250 mg/mL of Pseudostellaria heterophylla, and 160 mg/mL of Viola philippica.

(11) In one embodiment, the metastatic breast cancer is refractory metastatic breast cancer.

(12) In a preferred embodiment, the composition improves global health status/quality of life (GHS/QOL) scale of the subject, increases the level of CD3, CD4/CD8, CD19, and CD16+56 positive cells in the subject, and increases the physical, role, emotional, and cognitive functioning.

(13) In a preferred embodiment, the composition decreases fatigue and systemic therapy side effects.

(14) The global health status/quality of life (GHS/QOL) used herein is a standardized scale assessed by the self-administered European Organization for Research and Treatment of Cancer Quality of Life QuestionnaireCore 30 (EORTC-QLQ-C30). The functional scales such as physical, role, emotional, and cognitive as well as the symptom scales such as fatigue are a standardized scale assessed by the self-administered European Organization for Research and Treatment of Cancer Quality of Life QuestionnaireCore 30 (EORTC-QLQ-C30). The symptom scales such as systemic therapy side effect are assessed by the European Organization for Research and Treatment of Breast Cancer-Specific Quality of Life Questionnaire (EORTO-QLQ-BR23).

(15) A pharmaceutically effective amount is an amount effective to prevent, lower, stop or reverse the development of, or to partially or totally alleviate the existing symptoms of a particular condition for which the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art.

(16) The composition may be formulated for administration via sterile aqueous solution or dispersion, aqueous suspension, oil emulsion, water in oil emulsion, site-specific emulsion, long-residence emulsion, sticky-emulsion, microemulsion, nanoemulsion, liposomes, microparticles, microspheres, nanospheres, nanoparticles, minipumps, and with various natural or synthetic polymers that allow for sustained release. The compounds comprising the NRIP may also be formulated into aerosols, tablets, pills, sterile powders, suppositories, lotions, creams, ointments, pastes, gels, hydrogels, sustained-delivery devices, or other formulations used in drug delivery.

EXAMPLES

Experimental Design

(17) This study was a randomized, double-blind, placebo-controlled, parallel-group, phase IIa pilot trial in patients with metastatic breast cancer refractory to conventional treatment modalities. The primary outcome was the changes from baseline to post-treatment evaluations in the global health status/quality of life (GHS/QOL) standardized scale, assessed by the self-administered European Organization for Research and Treatment of Cancer Quality of Life QuestionnaireCore 30 (EORTC-QLQ-C30). The secondary outcomes included changes in functional and symptom scales, as well as the single items, of the EORTC-QLC-Q30 and -Breast Cancer 23 (BR23), immunomodulating effects of treatment on lymphocytes, and treatment-related adverse events. The study was approved by the Institutional Review Board (IRB) of the National Taiwan University Hospital, and written informed consents were obtained from all patients prior to entering the trial.

Participants

(18) Subjects were recruited at the National Taiwan University Hospital in Taipei, Taiwan between June 2009 and June 2011. The inclusion criteria were women, aged 20 to 80 years old, who had histologically or cytologically confirmed breast cancer with clinical evidence of progressive metastatic disease and any one of the following: a) no satisfactory response after primary or salvage treatment (i.e. chemotherapy, radiotherapy, surgery, or other approved therapies, such as target therapy or immuno-therapy), and b) no intention of accepting additional conventional treatments. Subjects were included provided that they had adequate bone marrow function with an absolute neutrophil count 1000/L, hemoglobin count 8 g/dL, and platelet count >75,000/L, and liver and renal function with total serum bilirubin <3 mg/dL and serum creatinine <2 mg/dL, respectively. Subjects of childbearing potential had to agree to use medically-accepted means of contraception during the participation of the study. Subjects must also have an estimated life expectancy of at least 4 weeks. All subjects had to give written informed consent to participate in the study.

(19) Subjects were excluded if they have ever received radiotherapy, endocrine therapy, antineoplastic drugs, or hormonal agents as adjuvant treatment or therapy for metastatic breast cancer within 2 weeks prior to entering the study. Additional exclusion criteria included uncontrolled infections, history of autoimmune disease (i.e. lupus erythematosus, ankylosing spondylosis, scleroderma or multiple sclerosis), prior history of other malignancies, with the exception of skin basal cell carcinoma, within 3 years of study entry, or any other serious diseases or medical history considered by the investigator to place the subject at increased risk. Subjects with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels above five times the upper limit of normal values, or if liver metastases were present, above ten times the upper limit of normal values, were excluded. Women who were lactating, pregnant, or planning to become pregnant were also excluded. Lastly, subjects were not eligible if they had participated in any other investigational study within 4 weeks of study entry.

(20) Subjects were withdrawn from the study if any of the following criteria were met: a) subject decided to withdraw her informed consent, b) the investigator considered the subject to be no longer physically or psychologically capable of remaining in the study, c) subject refused to proceed with critical measures for the study endpoints, defined as all variables required for the primary endpoint analysis, or d) subject developed adverse effects that the investigator considered as warranting discontinuation of the study treatment.

(21) Treatment Groups

(22) The study group received 1 vial (20 mL) of THL-P oral solution 3 times per day for 24 weeks. THL-P is an aqueous preparation that consists of extracts from 14 Chinese medicinal herbs. The active ingredients of THL-P oral solution (Sheng Foong Co., Ltd., I-Lan County, Taiwan) are Atractylodes macrocephaly (250 mg/ml), Astragalus membranaceus (330 mg/ml), Taraxacum mongolicum (500 mg/ml), Poria cocos (330 mg/ml), Ligusticum chuanxiong (25 mg/ml), Ligustrum lucidum (250 mg/ml), Codonopsis pilosula (250 mg/ml), Glycyrrhiza uralensis (160 mg/ml), Hedyotis diffusa (33 mg/ml), Pseudostellaria heterophylla (250 mg/ml), Viola philippica (160 mg/ml). The compositions, as well as the pharmacological and immunological effects, of these ingredients have been previously described. The control group received 1 vial (20 mL) of a matched placebo 3 times per day for 24 weeks.

(23) The investigators attempted to minimize the use of concomitant treatments in each subject throughout the study. If concomitant treatments were deemed necessary by the investigator, then it was ensured that a stable dose and therapy type was maintained throughout the study to minimize potential interference with the study endpoint assessments. Antipyretics on the day of injection were permitted, whereas all cancer treatments, with the exception of non-study-related local lesions palliative radiation therapy, were prohibited during the study.

Randomization and Blinding

(24) Treatment allocation was performed prior to site initiation, and each patient was assigned a unique number based on the order of enrolment. Patients meeting the eligibility criteria were randomly assigned in a 2:1 ratio to either the THL-P treatment group or placebo group. Randomization was achieved with the use of a permuted-block randomization algorithm with a block size of 6 in SAS 9.0 software (SAS Institute Inc., Cary, N.C. USA), where a list of sequential numbers was generated with each number randomly assigned to a group. All patients, caregivers, investigators, and outcome assessors were blinded to treatment assignment.

Measurement of Outcomes

(25) After randomization, several examinations were conducted at baseline and followed-up every 4 weeks for 24 weeks. The examinations included self-administered EORTC-QLQ-C30, EORTC-QLC-Q30 and -Breast Cancer 23 (BR23), body weight, collection of blood for assessment of T-lymphocyte activity, biochemistry and hematology tests.

(26) The primary endpoint was to evaluate the efficacy of the treatment in improving the QOL of patients from baseline to last visit. The changes in the GHS/QOL scale were assessed by the self-administered EORTC-QLQ-C30. The secondary outcomes evaluated the efficacy and safety of the treatment. The efficacy of the treatment was evaluated between baseline and last visit via the following measures: a) changes and maximum improvements in the functional and symptom standardized scales, as well as the single items, of the EORTC-QLC-Q30 and -Breast Cancer 23 (BR23), b) changes in body weight, c) immunomodulating effects of treatment on lymphocytes, as determined via phenotypic analyses of lymphocytes by flow cytometry (FACSCalibur, BD) with monoclonal antibodies for CD3, CD4, CD8, CD19, and CD16+56 and BD MultiSET software. The safety of the treatment was determined from the reports of adverse events.

Statistical Analyses

(27) The sample size for this study is arbitrarily determined to be 60 subjects for this pilot study to collect useful information for further study in the future. Demographic and clinical characteristics at baseline were analyzed according to randomized treatment groups. Primary and secondary endpoints were analyzed based on the intent-to-treat (ITT) population, which was defined as all randomized patients that received any treatment. Data of continuous variables are presented as meanstandard deviation. When the normality of these variables cannot be assumed, the data are presented as median (interquartile range). Data of categorical variables are presented as numbers (percentages). Statistical comparisons between continuous variables were made using the independent, two sample t-test. The Mann-Whitney U test was used to compare independent groups of data that were not normally distributed. A Fisher's exact test was used for comparisons of categorical variables. A parametric Student's paired t-test or non-parametric Wilcoxon signed ranks test were used to compare differences before and after treatment in each group. For all analyses, a two-sided P-value of <0.05 was considered significant. Statistical analyses were performed using SPSS 15.0 statistics software (SPSS Inc, Chicago, Ill., USA) and SAS 9.0 (SAS Institute Inc., Cary, N.C., USA).

Results

Study Population

(28) A total of 63 patients entered our trial between June 2009 and June 2011, and 19 patients were excluded due to lack of confidence in the treatment (n=10), hospital transfer (n=2), and treatment refusal (n=7). Overall, the screening failure rate was 30.2%, and 44 patients were randomly assigned in a 2:1 ratio to either the THL-P group (n=30) or the placebo group (n=14) (FIG. 1). Of these 44 patients, 39 had metastasis in bone, 19 in liver, 18 in lung, and 4 in brain. The demographic and clinical characteristics of the 44 randomized patients are summarized in Table 1. There were no statistically significant differences between the THL-P and placebo groups in age, height, body weight, stage of cancer (i.e. according to the TNM classification), duration of onset, and the scales and single items of the EORTO-QLQ-C30. Of the patients that were randomized to treatment, 31 patients (70.5%) did not complete the study. Their withdrawal reasons were listed in FIG. 1. In the THL-P group, 13 of 30 patients (43.3%) completed the study, while none of the patients in the placebo group completed the study. The ITT population comprised of 39 patients, with 28 patients in the THL-P group, and 11 patients in the placebo group.

(29) TABLE-US-00001 TABLE 1 Demographic and clinical characteristics of patients with refractory metastatic breast cancer at baseline. THL-P (n = 30) Placebo (n = 14) P-value Demographics Age (years).sup.1 60.68 9.49 58.74 7.63 0.507 Height (cm).sup.1 155.27 5.91 156.50 5.43 0.512 Weight (kg).sup.1 57.57 8.05 59.29 10.48 0.554 T stage, n (%).sup.2 T1 4 (13.4) 1 (7.2) T2 12 (40.0) 7 (50.0) 0.968 T3 7 (23.3) 3 (21.4) T4 7 (23.3) 3 (21.4) Lymph nodes, n (%).sup.2 N0 10 (33.3) 3 (12.4) N1 6 (20.0) 2 (14.3) 0.306 N2 4 (13.4) 2 (14.3) N3 10 (33.3) 7 (50.0) Metastasis, n (%).sup.2 M1 30 (100) 14 (100) N/A Duration of onset (years).sup.3 3.50 (2.00, 7.00) 4.13 (2.67, 5.42) 0.970 EORTO-QLQ-C30 GHS/QOL.sup.3 37.50 (16.67, 50.00) 50.00 (25.00, 66.67) 0.082 Functional scales Physical.sup.3 60.00 (46.67, 73.33) 70.00 (46.67, 86.67) 0.336 Role.sup.3 66.67 (33.33, 83.33) 66.67 (33.33, 100.00) 0.643 Emotional.sup.3 66.67 (50.00, 83.33) 75.00 (58.33, 91.67) 0.469 Cognitive.sup.3 66.67 (50.00, 83.33) 83.33 (66.67, 83.33) 0.118 Social.sup.3 66.67 (33.33, 100.00) 66.67 (66.67, 100.00) 0.711 Symptom scales Fatigue.sup.3 55.56 (33.33, 66.67) 38.89 (22.22, 55.56) 0.273 Nausea and vomiting.sup.3 0 (0, 16.67) 0 (0, 0) 0.362 Pain.sup.3 33.33 (0, 66.67) 8.33 (0, 50.00) 0.382 Single items Dyspnoea.sup.3 33.33 (0, 66.67) 0 (0, 33.33) 0.069 Insomnia.sup.3 33.33 (0, 33.33) 33.33 (0, 66.67) 0.608 Appetite loss.sup.3 33.33 (0, 66.67) 0 (0, 33.33) 0.367 Constipation.sup.3 0 (0, 33.33) 0 (0, 33.33) 0.403 Diarrhoea.sup.3 0 (0, 0) 0 (0, 33.33) 0.523 Financial difficulties.sup.3 33.33 (0, 33.33) 33.33 (0, 33.33) 0.746 Abbreviations: THL-P, Tien Hsien Liquid Practical; EORTO-QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30; GHS, global health status; and QOL, quality of life. P-values were determined via the independent, two sample t-test.sup.1, Fisher's exact test.sup.2, and Mann-Whitney U test.sup.3. Values are presented as mean standard deviation.sup.1, number (percentage).sup.2, and median (interquartile).sup.3.

Efficacy

(30) The primary endpoint, in particular, changes in the GHS/QOL standardized scale between the baseline and last visit of the ITT population, is presented in FIG. 2. There were significant increases in the GHS/QOL standardized scale between the baseline and last visit in the THL-P treatment group, whereas a significant decrease in the scale was found in the placebo group (P<0.05, FIG. 2A). Additionally, there was a significant difference between the THL-P and placebo group with respect to the change in the GHS/QOL scale from the baseline and last visit (41.69 vs. 33.33; P<0.001, FIG. 2B). These findings indicate that patients administered THL-P had a higher and improved QOL than those receiving a matched placebo. Thus, THL-P appears to be efficacious in improving the QOL of patients with refractory metastatic cancer.

(31) Table 2 presents the primary endpoints for changes in the standardized functional and symptom scales, as well as the single items, of the EORTO-QLQ-C30. There were significant increases in all five functional scales (i.e. physical, role, emotional, cognitive, and social) and a decrease in one symptom scale (i.e. fatigue) between the baseline and last visit of the THL-P treatment group (P<0.05). However, there were no significant differences between the baseline and last visit in the five functional scales, three symptom scales, and six single items of the EORTO-QLQ-C30 in the placebo group. Moreover, there were significant differences in the changes from baseline to last visit in physical, role, emotional, and cognitive functions, as well as fatigue, between the THL-P and placebo groups (P<0.05). There were no significant differences from baseline to last visit in the single items (i.e. dyspnoea, insomnia, loss of appetite, constipation, diarrhoea, and financial difficulties) of the EORTO-QLQ-C30 within and between the groups.

(32) TABLE-US-00002 TABLE 2 Primary endpoints: Changes in the functional and symptom scales of EORTO-QLQ-C30 in the intent-to-treat population. THL-P (n = 28) Placebo (n = 11) P-value Change from baseline EORTO-QLQ-C30 Functional scales Physical 13.33 (3.33, 26.67).sup. 0 (13.33, 13.33) 0.014* Role 0 (0, 41.67).sup. 0 (16.67, 0) 0.018* Emotional 8.33 (0, 25.00).sup. 0 (33.33, 8.33) 0.024* Cognitive 16.67 (0, 16.67).sup. 0 (33.33, 0) <0.001* Social 0 (0, 33.33).sup. 0 (33.33, 33.33) 0.379 Symptom scales Fatigue 22.22 (33.33, 11.11).sup. 0 (11.11, 22.22) <0.005* Nausea and vomiting 0 (0, 0) 0 (0, 16.67) 0.656 Pain 0 (25.00, 16.67) 0 (0, 16.67) 0.124 Single items Dyspnoea 0 (33.33, 0) 0 (0, 0) 0.528 Insomnia 0 (0, 16.67) 0 (0, 33.33) 0.569 Appetite loss 0 (0, 0) 0 (0, 0) 0.633 Constipation 0 (16.67, 0) 0 (0, 0) 0.770 Diarrhoea 0 (0, 33.33) 0 (0, 33.33) 0.866 Financial difficulties 0 (0, 0) 0 (0, 0) 0.747 Abbreviations: THL-P, Tien Hsien Liquid Practical; EORTO-QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30. *P <0.05 vs. placebo (Mann-Whitney U test). .sup.P <0.05 vs. baseline (Wilcoxon signed ranks test). Values are presented as median (interquartile).

(33) The secondary endpoints for changes in the standardized functional and symptom scales the EORTO-QLQ-BR23 are presented in Table 3. There were significant increases in the body image and future perspective scales (i.e. two of the four functional scales) and a decrease in the systemic therapy side effects, arm symptoms, and upset by hair loss scales (i.e. three of the four symptom scales) between the baseline and last visit of the THL-P treatment group (P<0.05). However, there were no significant differences between the baseline and last visit in any of the functional or symptom scales of the EORTO-QLQ-BR23 in the placebo group. Moreover, there was a significant difference in the changes from baseline to last visit in systemic therapy side effects scale between the THL-P and placebo groups (P<0.05). Lastly, there were no significant differences in the body weights (i.e. % change) of the two groups between the baseline and last visit (Table 3).

(34) TABLE-US-00003 TABLE 3 Secondary endpoints: Changes in the functional and symptom scales of EORTO-QLQ-BR23, lymphocytes, and body weight in the intent-to-treat population. THL-P (n = 28) Placebo (n = 11) P-value Change from baseline EORTO-QLQ-BR23 Functional scales.sup.1 Body image 0 (0, 33.33).sup. 0 (0, 8.33) 0.346 Sexual function 0 (0, 0) 0 (0, 0) 0.591 Sexual enjoyment 0 (0, 0) 16.67 (0, 33.33) 0.582 Future perspective 16.67 (0, 33.33).sup. 0 (0, 0) 0.102 Symptom scales.sup.1 Systemic therapy side effects 4.76 (23.81, 0).sup. 4.76 (4.76, 9.52) 0.010* Breast symptoms 0 (16.67, 8.33) 0 (8.33, 0) 0.450 Arm symptoms 5.56 (33.33, 0).sup. 0 (11.11, 22.22) 0.346 Upset by hair loss 33.33 (33.33, 0).sup. 0 (16.67, 0) 0.316 Lymphocytes (%) CD3 6.0 (1.0, 9.5).sup. 2.5 (6.0, 1.0) 0.001* CD4 0.0 (2.0, 8.0) 1.5 (4.0, 1) 0.157 CD8 1.5 (3.0, 1.5) 0.5 (2.0, 2.0) 0.387 CD4/CD8 0.20 (0.05, 0.51).sup. 0.11 (0.19, 0.00) 0.043* CD19 3.0 (0.0, 7.5).sup. 2.0 (3.0, 3.0) 0.021* CD16 + 56 8.0 (3.0, 11.0).sup. 4.0 (6.0, 3.0).sup. <0.001* Body weight (%).sup.2 0.24 3.36 0.30 4.04 0.964 Abbreviations: THL-P, Tien Hsien Liquid Practical; EORTO-QLQ-BR23, European Organization for Research and Treatment of Breast Cancer-Specific Quality of Life Questionnaire. *P <0.05 vs. placebo (Mann-Whitney U test.sup.1 or independent, two sample test.sup.2). .sup.P <0.05 vs. baseline (Wilcoxon signed ranks test.sup.1 or paired Student's t-test.sup.2). Values are presented as median (interquartile).sup.1 and mean standard deviation.sup.2.

Safety

(35) The treatment-related adverse events reported during the study were mild constipation (n=6) and localized itching (n=1). Constipation was relieved by increasing water intake, and itching subsided immediately after cessation of all medication. No nausea, vomiting, hair loss, diarrhoea, and heavy constipation were observed. Nine severe adverse events were reported by five participants. However, all serious adverse events were considered unrelated to THL-P treatment by the IRB.

(36) Immunomodulating Effects

(37) There were significant differences in the changes from baseline to the last visit in CD3, CD4/CD8, CD19, and CD16+56 positive cells between the THL-P and placebo groups (P<0.05) (Table 3). Furthermore, there were significant increases in CD3, CD4/CD8, CD19, and CD16+56 levels from baseline to the last visit in the THL-P group, whereas there was a significant decrease in CD16+56 from baseline to the last visit in the placebo group (P<0.05) (Table 3).

Discussion

(38) In patients with refractory metastatic breast cancer, the oral administration of 20 mL THL-P three times a day for 24 weeks significantly improved the QOL, increased the physical, role, emotional, and cognitive functioning, decreased fatigue and systemic therapy side effects, and had immunomodulating effects on lymphocytes. Furthermore, THL-P treatment did not induce any severe adverse events, and the only side effects reported were mild constipation and localized itching. Together, these findings suggest that THL-P is a safe and effective CAM for patients with refractory metastatic breast cancer.

(39) Currently, no global consensus or guidelines exist for the treatment of patients with metastatic breast cancer, especially for those refractory to conventional treatments. Furthermore, it is estimated that anywhere from 48-98% of all breast cancer patients use some form of CAM. Interestingly, achieving the best quality of life (QOL) is one of the main goals of conventional treatments, as well as reasons for using CAM. It was recently reported that the GHS/QOL scale, assessed via the EORTC-QLQ-C30, can serve as an important predictor of response to treatment, PFS, and OS in women with metastatic breast cancer. In the present study, which used the same questionnaire to assess the GHS/QOL, as well as the function and symptom scales, found that THL-P was effective in improving the QOL and functions of refractory metastatic breast cancer patients. Given these positive findings, larger trials examining the effects of THL-P on other pertinent outcomes, such as PFS and OS, are warranted.

(40) The use of CAM has been on the rise worldwide, especially among patients with life-threatening diseases, such as cancer. There are also marked cultural differences in the way CAM is integrated into breast cancer treatment regiments. In Asian populations, including Taiwan, the use of traditional Chinese medicines is very common and enjoys widespread popularity. However, the use of CAM may be associated with severe adverse effects or CAM-drug interactions with conventional treatments for breast cancer, and consequently their safety and efficacy warrant investigation via randomized and controlled clinical trials. In this randomized, double-blind, placebo-controlled, parallel-group, phase IIa trial, it was found that THL-P was not only an effective CAM in patients with refractory metastatic breast cancer, but also a safe alternative adjuvant, since there were no serious adverse events reported with its use. Although these findings suggest that the use of THL-P is safe and effective, studies that examine the safety of using THL-P, as well as other CAM, in combination with conventional treatments are needed.

(41) In the present study, there were more withdrawal cases in the placebo group than in the THL-P treatment group. Given that this was a double-blinded study, where the patients, caregivers, investigators, and outcome assessors were blinded to treatment, we speculate that the significant difference in the number of withdrawal cases between the control and study groups suggests that THL-P may have possible therapeutic effects in patients with refractory metastatic breast cancer, which requires further investigation.

(42) Although not directly studied, the therapeutic efficacy of THL-P in patients with metastatic breast cancer can be extended to its anti-metastatic, anti-angiogenic, and anti-tumour effects, as previously demonstrated via in vitro and in vivo preclinical studies. Furthermore, corroborating the observations of the present study, THL-P was also found not to have any adverse effects on the body weights of immunocompromised mice. In addition to its anticancer effects, THL-P was found to have immunomodulating effects, specifically in reducing cytokine production of T-lymphocytes isolated from patients with recurrent aphthous ulcerations. Herein, we also demonstrated that THL-P has immunomodulating effects in patients with refractory metastatic breast cancer. Specifically, we found that there were marked differences in the changes from baseline to the last visit in CD3, CD4/CD8, CD19, and CD16+56 positive cells between the THL-P and placebo groups. Although our study provided the first clinical evidence for the safety and efficacy of using THL-P in refractory metastatic breast cancer patients, future studies assessing the specific mechanisms responsible for its immunomodulating effects in this population are warranted.

(43) CAM are widely used by breast cancer patients, however their safety and efficacy have been studied in very few randomized and controlled clinical trials. The present study is one of a few to provide safety and efficacy evidence for a CAM that was beyond empirical evidence, case studies, and hypothetical physiological effects. Despite these important findings, there are several limitations in the present study, including that this was a single-site study with a small sample size, and that THL-P is a compound with multiple ingredients. Therefore, further investigations on the exact therapeutic mechanisms for each ingredient of THL-P, as well as multiple site, large-scale studies that confirm and extend the safety and efficacy findings of the present study, are warranted.

Conclusions

(44) Our findings suggest that an oral administration of 20 mL THL-P three times a day for 24 weeks significantly improves the QOL, increases the physical, role, emotional, and cognitive functioning, decreases fatigue and systemic therapy side effects, and has immunomodulating effects on lymphocytes in patients with refractory metastatic breast cancer. Additionally, THL-P treatment did not induce any severe adverse events. Together, these findings suggest that THL-P is a safe and effective CAM for patients with refractory metastatic breast cancer.